Key result
Dexmedetomidine improved memory function at 30 days post-surgery compared to midazolam in patients undergoing coronary artery bypass graft surgery.
Why the study?
Postoperative cognitive decline is common after general anesthesia, prompting an evaluation of the effects of dexmedetomidine versus midazolam during CABG surgery on cognitive and memory function.
Does dexmedetomidine improve postoperative cognitive and memory function compared to midazolam in patients undergoing elective on-pump CABG?
RCT (n=42)
Double-blind
Electronically randomized method
Yes
Does dexmedetomidine improve postoperative cognitive and memory function compared to midazolam in patients undergoing elective on-pump CABG?
Dexmedetomidine may have a lower impact on postoperative cognitive and memory function compared to midazolam in patients undergoing CABG.
Answers are grounded in this paper and cite their sources.
Dexmedetomidine may better preserve cognition than midazolam after CABG; extends small RCT data on sedation choice in cardiac surgery.
Background: Postoperative cognitive decline is a common complication observed frequently after general anesthesia in the immediate postoperative phase. We studied the effects of dexmedetomidine versus midazolam during coronary artery bypass graft (CABG) surgery on cognitive and memory function. Methods: In this clinical trial, 42 elective on-pump CABG candidates under general anesthesia, aged between 40 and 65 years, were enrolled randomly in 2 groups. Group A received 0.05–0.1 mg/kg of midazolam and Group B received 1 µg/kg of dexmedetomidine. One day before surgery, all the participants underwent the Persian version of the Mini-Mental State Examination (MMSE) and the Persian version of the Wechsler Memory Scale (WMS) test for a comparison of cognitive impairment and memory functions. Both groups were given fentanyl and propofol for the induction of anesthesia and muscle relaxants. The MMSE and WMS tests were repeated 5 and 30 days after surgery. Results: The mean±SD of age was 55.47±7.18 y in Group A and 55.39±6.08 y in Group B. Eighty percent of the participants were men in both groups. There were no significant differences between Group A and Group B in the MMSE and WMS before surgery (89.04±14.30 vs. 97.10±18.10, respectively; P=0.059), but the WMS was significantly different 30 days after surgery (87.60±14.30 vs. 103.53±19.93, respectively; P=0.005). Group A showed high cognitive impairment and low WMS scores compared with Group B (P=0.005). Additionally, the MMSE results were not statistically different between the 2 groups postoperatively (24.80±3.18 vs. 23.55±4.18, respectively; P=0.394). Conclusion: Our results showed that dexmedetomidine might have a lower impact on cognitive function than might midazolam among patients undergoing CABG. J Teh Univ Heart Ctr 2019;14(2):67-73 This paper should be cited as: Rajaei M, Tabari M, Soltani G, Alizadeh K, Nazari A, Noroozian M, Morovatdar N. Dexmedetomidine and Midazolam on Postoperative Cognitive Impairment after Coronary Artery Bypasses Graft Surgery: A Randomized Clinical Trial. J Teh Univ Heart Ctr 2019;14(2):67-73.
No takes yet. Share an insight, caveat, or question.
Rajaei et al. (2019) conducted an RCT in Postoperative cognitive impairment (n=42). Dexmedetomidine vs. Midazolam (0.05–0.1 mg/kg) was evaluated on Wechsler Memory Scale (WMS) score at 30 days after surgery (p=0.005). Dexmedetomidine improved memory function at 30 days post-surgery compared to midazolam in patients undergoing coronary artery bypass graft surgery.
Synapse has enriched 10 related papers. Consider them for comparative context: